DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma — DREAM3R  

Mesothelioma Malignant Advanced Clinical Trial

Official title: DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness of durvalumab in combination with standard chemotherapy for mesothelioma. All participants in the study will receive standard first-line chemotherapy for mesothelioma. Two thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab. Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed death-ligand 1 (PD-L1).

Blocking PD-L1 helps the body's immune system to attack cancer cells. Research has shown that durvalumab can slow tumour growth and shrink tumours in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma.

This international study is being led jointly by the University of Sydney in Australia, and the Pr Eastern Cooperative Oncology Group (PrECOG) in the USA. The study plans to enrol 480 participants from hospitals throughout Australia, New Zealand and the USA.

Clinical Trial Description

The purpose of this study is to investigate the effectiveness of durvalumab in combination with standard chemotherapy for mesothelioma. All participants in the study will receive standard first-line chemotherapy for mesothelioma. Two thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab. Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called PD-L1.

Blocking PD-L1 helps the body's immune system to attack cancer cells. Research has shown that durvalumab can slow tumour growth and shrink tumours in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma.

This international study is being led jointly by the University of Sydney in Australia, and the PrECOG Oncology group in the USA. The study plans to enrol 480 participants from hospitals throughout Australia, New Zealand and the USA. ;

Related Conditions & MeSH terms

• Mesothelioma
• Mesothelioma Malignant Advanced

• NCT number: NCT04181411
• Study type: Interventional
• Source: University of Sydney
• Contact: Project Manager
• Phone: +61 2 9562 5000
• Email: dream3r@ctc.usyd.edu.au
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: March 2020
• Completion date: June 2024